Ocugen posted a GAAP net loss of $24.88 million, or $0.07 per share, for Q2 2026, versus a loss of $14.74 million, or $0.05 per share, a year earlier.
Revenue edged up to $1.49 million from $1.37 million, while operating loss widened to $16.44 million from $13.8 million.
Operating expenses rose to $17.93 million from $15.17 million, led by R&D costs of $10.69 million and G&A of $7.24 million.
Cash position and pipeline updates
Cash, cash equivalents and restricted cash climbed to $100.4 million at June 30 from $32.2 million at March 31, following a $130 million6.75% Convertible Senior Notes due 2034 offering.
The FDA cleared a Phase 3 OCU410 trial in geographic atrophy and granted RMAT status; top-line data remain targeted for in .
OCGN•
